



*vaccines*



an Open Access Journal by MDPI

## Advances in Vaccine Biomanufacturing Processes

Guest Editor:

**Prof. Dr. Olivier Henry**

Department of Chemical  
Engineering, Polytechnique  
Montréal, Montréal, QC, Canada

Deadline for manuscript  
submissions:

**closed (20 April 2022)**

### Message from the Guest Editor

The aim of this special issue is to present significant advances made in bioprocessing for the robust, rapid, flexible and cost-efficient manufacturing of vaccines. Contributions are welcomed on a range of themes, including process intensification of upstream and downstream operations allowing improved productivity and increased product yield and purity, the development and application of new process analytical technologies to support process development and analyses of the product quality attributes, the design of novel monitoring tools and control strategies to ensure process consistency and performance, the application of new high-throughput technologies and Quality by Design approaches for vaccine manufacturing, as well as the devise of new cell line platforms, innovative bioreactor designs and downstream processing techniques. Since rational process development and optimization are highly dependent on a good understanding of the complex production steps and interactions between cells and virus, contributions related to the modelling of cell culture kinetics, as well as the application of systems biology and metabolic engineering approaches are also welcomed.



[mdpi.com/si/94494](https://mdpi.com/si/94494)

**Special** issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)